Item
Ascorbic Acid (60VITCAA000)
Ascorbic Acid
Chemical solvents: Methanol (≤3000 ppm) - Methanol is a raw material for Vitamin C.
Nutrient / Vitamin
Attributes
- Gluten-free
- Halal
- Ingredient declaration
- Kosher
- PHO-free
- Vegan
- Non-GMO
Locations
| Location name | Address |
|---|---|
| Anhui Sealong | Mohekou Industrial Park Wuhe County, Bengbu 233316 CHN |
| CSPC Weisheng Pharmaceutical | No. 236 Huanghe Road New-High Technology Industry Development Shijiazhung, Shijiazhung N/A CHN |
| Ningxia | No. 1 Qiyuan street Wangyuan Industrial Area Yinchuan, Yinchuan 750101 CHN |
| Northeast Pharmaceutical Group | No. 37, Zhonggong Bei Street Tiexi District Shenyang, LN 110026 CHN |
| Shandong Luwei Pharmaceutical | Shuangfeng Industrial Park Zichuan District Zibo City, Shandong Province N/A CHN |
Documents
| Type | Location | File name | Effective | Expiration |
|---|---|---|---|---|
| Allergens | Northeast Pharmaceutical Group | Allergens.pdf | 9/12/2022 | 9/11/2024 |
| Allergens | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | Allergens.pdf | 6/25/2024 | 6/25/2026 |
| Allergens | Ningxia | Allergens.pdf | 9/3/2024 | 9/3/2026 |
| Allergens | Shandong Luwei Pharmaceutical | Allergens.pdf | 9/3/2024 | 9/3/2026 |
| Allergens | CSPC Weisheng Pharmaceutical | Allergens.pdf | 1/22/2025 | 1/22/2027 |
| No Animal Ingredient Statement | Shandong Luwei Pharmaceutical | Allergens-VC-Luwei.pdf | 3/30/2018 | 3/30/2019 |
| No Animal Ingredient Statement | Northeast Pharmaceutical Group | Allergens-VC-NEPG.pdf | 4/19/2018 | 4/19/2019 |
| BSE - TSE | Ningxia | BSE_TSE Statement-VC-Ningxia Qiyuan (1).pdf | 1/23/2020 | 1/22/2023 |
| BSE - TSE | CSPC Weisheng Pharmaceutical | BSE_TSE-VC-Weisheng.pdf | 1/29/2022 | 1/28/2025 |
| California Prop. 65 | CSPC Weisheng Pharmaceutical | CA Prop 65-VC-CSPC Weisheng.pdf | 1/28/2025 | 1/28/2027 |
| California Prop. 65 | Shandong Luwei Pharmaceutical | CA Prop 65-VC-Luwei.pdf | 1/24/2025 | 1/24/2027 |
| California Prop. 65 | Ningxia | CA Prop 65-VC-Ningxia Qiyuan.pdf | 1/24/2025 | 1/24/2027 |
| CoA Sample | Shandong Luwei Pharmaceutical | COA Example-VC-Luwei.pdf | 9/8/2024 | 9/8/2026 |
| CoA Sample | Ningxia | coa_230319c03.pdf | 3/23/2023 | 3/22/2025 |
| Ingredient Statement | Northeast Pharmaceutical Group | Composition Statement-Ascorbic Acid-NEPG.pdf | 8/22/2017 | 8/22/2018 |
| Ingredient Statement | Shandong Luwei Pharmaceutical | Composition-VC-Luwei.pdf | 2/27/2023 | 2/26/2026 |
| Ingredient Statement | Ningxia | Composition-VC-Ningxia Qiyuan.pdf | 1/2/2025 | 1/2/2028 |
| Ingredient Statement | CSPC Weisheng Pharmaceutical | Composition-VC-Weisheng (2).pdf | 3/5/2024 | 3/5/2025 |
| Country of Origin | Northeast Pharmaceutical Group | Country of Origin.pdf | 12/14/2022 | 12/13/2025 |
| Country of Origin | CSPC Weisheng Pharmaceutical | Country of Origin.pdf | 6/3/2024 | 6/3/2027 |
| Country of Origin | Ningxia | Country of Origin.pdf | 12/28/2024 | 12/28/2027 |
| Country of Origin | Shandong Luwei Pharmaceutical | Country of Origin.pdf | 1/22/2025 | 1/22/2028 |
| Country of Origin | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | Country of Origin.pdf | 3/19/2025 | 3/18/2028 |
| HACCP Process Flow Diagram | Shandong Luwei Pharmaceutical | Flow Chart with CCPs-VC-Luwei.pdf | 1/24/2025 | 1/24/2027 |
| HACCP Process Flow Diagram | Northeast Pharmaceutical Group | Flow Chart with CCPs-VC-NEPG 1.pdf | 3/19/2021 | 3/19/2023 |
| HACCP Process Flow Diagram | CSPC Weisheng Pharmaceutical | Flow Chart with CCPs-VC-Weisheng (2).pdf | 4/17/2024 | 4/17/2026 |
| HARPC Food Safety Plan (Item) | Ningxia | Food Safety-VC-Ningxia Qiyuan.pdf | 1/23/2020 | 1/22/2023 |
| Food Contact Packaging Certificate of Compliance | Ningxia | Foreign Body Control-VC-Ningxia Qiyuan (1).pdf | 2/25/2020 | 2/24/2022 |
| GMO | Northeast Pharmaceutical Group | GMO free Statement-VC-NEPG.pdf | 6/6/2019 | 6/5/2021 |
| GMO | Shandong Luwei Pharmaceutical | GMO-VC-Luwei.pdf | 4/1/2025 | 4/1/2027 |
| GMO | Ningxia | GMO-VC-Ningxia Qiyuan.pdf | 1/8/2025 | 1/8/2027 |
| GMO | CSPC Weisheng Pharmaceutical | GMO-VC-Weisheng (1).pdf | 3/5/2024 | 3/5/2026 |
| GMO | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | GMO-VC-Weisheng.pdf | 3/5/2024 | 3/5/2027 |
| GRAS/NDI/ODI Statement | CSPC Weisheng Pharmaceutical | GRAS Statement-VC-Weisheng.pdf | 2/21/2019 | 2/20/2022 |
| GRAS/NDI/ODI Statement | Ningxia | GRAS-VC-Ningxia Qiyuan.pdf | 1/23/2020 | 1/22/2023 |
| HACCP Process Flow Diagram | Ningxia | HACCP Flow Chart (CCP)-VC-Ningxia Qiyuan.pdf | 2/4/2025 | 2/4/2027 |
| HACCP | Ningxia | HACCP Plan-VC-Ningxia Qiyuan.pdf | 1/2/2025 | 1/2/2028 |
| HACCP | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | HACCP Plan-VC-CSPC Weisheng.pdf | 8/16/2024 | 8/16/2027 |
| HACCP | CSPC Weisheng Pharmaceutical | HACCP Plan-VC-Weisheng (1).pdf | 4/17/2024 | 4/17/2027 |
| HACCP | Northeast Pharmaceutical Group | HACCP-Plan-VC-NEPG.pdf | 1/31/2024 | 1/30/2027 |
| HACCP | Shandong Luwei Pharmaceutical | HACCP-VC-Luwei.pdf | 1/17/2024 | 1/16/2027 |
| Halal | Shandong Luwei Pharmaceutical | Halal (MUI)-Luwei-29.11.2026.pdf | 11/30/2022 | 11/29/2026 |
| Halal | Northeast Pharmaceutical Group | Halal (MUI)-NEPG_Shenxiliu+Kunminghu-06.12.2026.pdf | 12/7/2022 | 12/6/2026 |
| Halal | Ningxia | Halal (SHC)-N. Qiyuan-16.05.2027.pdf | 4/24/2024 | 5/16/2027 |
| Halal | CSPC Weisheng Pharmaceutical | HALAL-CSPC Weisheng-27.07.2026.pdf | 7/28/2022 | 7/27/2026 |
| Heavy Metal | Shandong Luwei Pharmaceutical | Heavy Metals-VC-Luwei.pdf | 2/13/2025 | 2/13/2027 |
| Heavy Metal | Northeast Pharmaceutical Group | Heavy Metals-VC-NEPG.pdf | 3/27/2023 | 3/26/2025 |
| Heavy Metal | Ningxia | Heavy Metals-VC-Ningxia Qiyuan.pdf | 10/20/2022 | 10/19/2024 |
| Heavy Metal | CSPC Weisheng Pharmaceutical | Heavy Metals-VC-Weisheng (3).pdf | 6/13/2023 | 6/12/2025 |
| Heavy Metal | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | Heavy Metals-VC-Weisheng.pdf | 6/13/2023 | 6/12/2025 |
| Label Sample | Northeast Pharmaceutical Group | image1.jpeg | 2/2/2023 | 2/2/2024 |
| Irradiation Status Statement | Northeast Pharmaceutical Group | Ionization_Radiation-VC-NEPG.pdf | 8/22/2017 | 8/22/2019 |
| Irradiation Status Statement | Shandong Luwei Pharmaceutical | Ionizing_Radiation-VC-Luwei (2).pdf | 3/1/2019 | 2/28/2021 |
| Irradiation Status Statement | Ningxia | Ionizing_Radiation-VC-Ningxia Qiyuan (1).pdf | 1/23/2020 | 1/22/2022 |
| Irradiation Status Statement | CSPC Weisheng Pharmaceutical | Ionizing_Radiation-VC-Weisheng.pdf | 6/5/2024 | 6/5/2026 |
| Item Questionnaire | Northeast Pharmaceutical Group | Item Questionnaire.pdf | 9/4/2021 | 9/3/2024 |
| Item Questionnaire | Shandong Luwei Pharmaceutical | Item Questionnaire.pdf | 6/4/2024 | 6/4/2027 |
| Item Questionnaire | CSPC Weisheng Pharmaceutical | Item Questionnaire.pdf | 1/23/2025 | 1/23/2028 |
| Kosher | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | Kosher-CSPC Weisheng-31.08.2025.pdf | 8/27/2024 | 8/31/2025 |
| Kosher | CSPC Weisheng Pharmaceutical | Kosher-CSPC Weisheng-31.08.2025.pdf | 8/27/2024 | 8/31/2025 |
| Kosher | Shandong Luwei Pharmaceutical | Kosher-Luwei-31.03.2026.pdf | 3/25/2025 | 3/31/2026 |
| Kosher | Northeast Pharmaceutical Group | Kosher-NEPG-30.09.2024.pdf | 9/26/2023 | 9/30/2024 |
| Kosher | Ningxia | Kosher-Ningxia Qiyuan-30.11.2025.pdf | 11/7/2024 | 11/30/2025 |
| Lot Code | Ningxia | Lot Code Explanation-VC-Ningxia Qiyuan.pdf | 1/24/2025 | 1/24/2028 |
| Melamine | Ningxia | Melamine Declaration-VC-Ningxia Qiyuan.pdf | 1/23/2020 | 1/22/2021 |
| Melamine | CSPC Weisheng Pharmaceutical | Melamine Statement-VC-Weisheng.pdf | 10/15/2018 | 10/15/2019 |
| Safety Data Sheet (SDS) | Shandong Luwei Pharmaceutical | MSDS-VC-Luwei.pdf | 2/27/2023 | 2/26/2026 |
| Safety Data Sheet (SDS) | Northeast Pharmaceutical Group | MSDS-VC-NEPG 1.PDF | 2/21/2020 | 2/20/2023 |
| Natural | Northeast Pharmaceutical Group | Non-Organic Affidavit-VC-NEPG.pdf | 2/13/2018 | 2/13/2019 |
| CoA Sample | CSPC Weisheng Pharmaceutical | NotApplicable_COASample.pdf | 11/1/2024 | 11/1/2026 |
| Nutrition | Northeast Pharmaceutical Group | NotApplicable_Nutrition.pdf | 3/23/2021 | 3/22/2024 |
| Organic | Northeast Pharmaceutical Group | NotApplicable_Organic.pdf | 3/19/2018 | 3/19/2023 |
| Organic | Ningxia | NotApplicable_Organic.pdf | 3/19/2018 | 3/19/2023 |
| Nutrition | Ningxia | Nutrition.pdf | 6/24/2024 | 6/24/2027 |
| Nutrition | Shandong Luwei Pharmaceutical | Nutrition.pdf | 9/9/2024 | 9/9/2027 |
| Nutrition | CSPC Weisheng Pharmaceutical | Nutrition.pdf | 1/22/2025 | 1/22/2028 |
| Natural | Shandong Luwei Pharmaceutical | Origin-VC-Luwei.pdf | 1/24/2025 | 1/24/2026 |
| Natural | CSPC Weisheng Pharmaceutical | Origin-VC-Weisheng.pdf | 10/9/2024 | 10/9/2025 |
| Food Contact Packaging Certificate of Compliance | Northeast Pharmaceutical Group | Packaging-VC-NEPG.pdf | 11/18/2022 | 11/17/2024 |
| Pesticide | Shandong Luwei Pharmaceutical | Purity-VC-Luwei.pdf | 7/21/2022 | 7/20/2024 |
| Pesticide | CSPC Weisheng Pharmaceutical | Purity-VC-Weisheng (1).pdf | 7/24/2023 | 7/23/2025 |
| CoA Sample | Northeast Pharmaceutical Group | Recall program-NEGP.pdf | 3/12/2021 | 3/12/2023 |
| Food Contact Packaging Certificate of Compliance | Shandong Luwei Pharmaceutical | Requirements for packed Raw Materials-VC DC 97 (SF)-Luwei.pdf | 8/10/2023 | 8/9/2025 |
| Label Sample | Shandong Luwei Pharmaceutical | Requirements for packed Raw Materials-VC-Luwei.pdf | 1/24/2025 | 1/24/2026 |
| Lot Code | Shandong Luwei Pharmaceutical | Requirements for packed Raw Materials-VC-Luwei.pdf | 1/24/2025 | 1/24/2028 |
| Label Sample | Ningxia | Requirements for packed Raw Materials-VC-Ningxia Qiyuan (3).pdf | 1/24/2025 | 1/24/2026 |
| Lot Code | Northeast Pharmaceutical Group | Requirements packed raw material-VC-NEPG.pdf | 12/5/2022 | 12/4/2025 |
| Food Contact Packaging Certificate of Compliance | CSPC Weisheng Pharmaceutical | Requirements for packed Raw Materials-VC-Weisheng.pdf | 12/23/2024 | 12/23/2026 |
| Lot Code | CSPC Weisheng Pharmaceutical | Requirements for packed Raw Materials-VC-Weisheng.pdf | 1/28/2025 | 1/28/2028 |
| Label Sample | CSPC Weisheng Pharmaceutical | Requirements for packed Raw Materials-VC-Weisheng.pdf | 1/28/2025 | 1/28/2026 |
| Label Sample | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | Requirements for packed Raw Materials-VC-Weisheng.pdf | 11/21/2024 | 11/21/2025 |
| Residual Statement | Shandong Luwei Pharmaceutical | Residual Solvents_2009_32_EC-VC-Luwei.pdf | 1/22/2025 | 1/22/2026 |
| Residual Statement | CSPC Weisheng Pharmaceutical | Residual Solvents-VC-CSPC Weisheng.pdf | 1/23/2025 | 1/23/2026 |
| Residual Statement | Ningxia | Residual Solvents-VC-Ningxia Qiyuan.pdf | 2/25/2020 | 2/24/2021 |
| Residual Statement | Northeast Pharmaceutical Group | Residual Solvent-Test Method-VC-NEPG.pdf | 11/18/2022 | 11/18/2023 |
| Safety Data Sheet (SDS) | CSPC Weisheng Pharmaceutical | SDS-VC-CSPC Weisheng.pdf | 1/22/2025 | 1/22/2028 |
| Safety Data Sheet (SDS) | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | SDS-VC-CSPC Weisheng.pdf | 3/27/2025 | 3/26/2028 |
| Safety Data Sheet (SDS) | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | SDS-VC-CSPC Weisheng.pdf | 3/27/2025 | 3/26/2028 |
| Safety Data Sheet (SDS) | Ningxia | SDS-VC-Ningxia Qiyuan.pdf | 1/2/2025 | 1/2/2028 |
| Sewage Statement | Shandong Luwei Pharmaceutical | Sewage Sludge Statement-VC-Luwei.pdf | 3/2/2018 | 3/1/2020 |
| Sewage Statement | Northeast Pharmaceutical Group | Sewage Sludge Statement-VC-NEPG.pdf | 4/10/2018 | 4/9/2020 |
| Sewage Statement | CSPC Weisheng Pharmaceutical | Sewage Sludge Statement-VC-Weisheng.pdf | 10/15/2018 | 10/14/2020 |
| Sewage Statement | Ningxia | Sewage Sludge-VC-Ningxia Qiyuan.pdf | 10/24/2022 | 10/23/2024 |
| Shelf Life | Shandong Luwei Pharmaceutical | Shelf Life-VC-Luwei.pdf | 2/13/2025 | 2/13/2028 |
| Shelf Life | Ningxia | Shelf Life-VC-Ningxia Qiyuan.pdf | 12/28/2024 | 12/28/2027 |
| Shelf Life | CSPC Weisheng Pharmaceutical | Shelf Life-VC-Weisheng (1).pdf | 3/5/2024 | 3/5/2026 |
| Shelf Life | Northeast Pharmaceutical Group | Shelf-life-VC-NEPG-2022.pdf | 3/23/2022 | 3/22/2025 |
| Product Specification Sheet | CSPC Weisheng Pharmaceutical | Specification-48 months-VC-USP-FCC-E300-BP-EP-Weisheng (1).pdf | 4/12/2023 | 4/11/2026 |
| Product Specification Sheet | Shandong Luwei Pharmaceutical | Specification-BP2016-USP40-FCC10-E300-EP10-VC-Luwei.pdf | 9/3/2024 | 9/3/2027 |
| Product Specification Sheet | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | Specifications-VC (USP-FCC-E300-BP-EP)-CSPC Weisheng.pdf | 1/6/2025 | 1/6/2028 |
| Product Specification Sheet | ACT of NA, Inc, - CSPC Weisheng Pharmaceutical (Shijiazhuang) Co., Ltd., China | Specifications-VC (USP-FCC-E300-BP-EP)-CSPC Weisheng.pdf | 1/6/2025 | 1/6/2028 |
| Product Specification Sheet | Ningxia | Specification-VC-E300-EP-BP-USP-FCC-Ningxia Qiyuan (1).pdf | 1/6/2023 | 1/5/2026 |
| Product Specification Sheet | Northeast Pharmaceutical Group | Specification-VC-EP-BP-USP-FCC-E300-NEPG.pdf | 5/1/2022 | 4/30/2025 |
| Suitability Requirements | Northeast Pharmaceutical Group | Suitability Requirements.pdf | 9/4/2021 | 9/3/2024 |
| Suitability Requirements | Ningxia | Suitability Requirements.pdf | 9/12/2022 | 9/11/2025 |
| Suitability Requirements | Shandong Luwei Pharmaceutical | Suitability Requirements.pdf | 10/10/2023 | 10/9/2026 |
| Suitability Requirements | CSPC Weisheng Pharmaceutical | Suitability Requirements.pdf | 1/23/2025 | 1/23/2028 |
-
Documents Up to Date
- 56 locations
- 54 items
- 600 documents